Sunday, May 17, 2026 | Hyatt Regency Orlando, Ballroom TUV
Doors Open: 6:30pm
Please join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD and the importance of identifying appropriate patients for treatment.
This presentation is intended for US HCPs only. The FDA-approved indications for JASCAYD® are for the US and may or may not be approved in other jurisdictions.
INDICATIONS
JASCAYD is indicated for:
- the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
- the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
- The most common adverse reactions with an incidence of ≥5% in patients treated with JASCAYD were diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness.
DRUG INTERACTIONS
Effects of Other Drugs on JASCAYD
- Strong CYP3A Inhibitors: Reduce the dosage of JASCAYD to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with a strong CYP3A inhibitor increases exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions.
- Moderate or Strong CYP3A Inducers: Avoid use of JASCAYD with strong or moderate CYP3A inducers. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with moderate or strong CYP3A inducers is expected to decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD.
- Pirfenidone: Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg twice daily. Concomitant use of JASCAYD with pirfenidone decreases exposure of nerandomilast. When JASCAYD was used concomitantly with pirfenidone in patients with IPF in FIBRONEER-IPF, efficacy was not observed with the JASCAYD 9 mg twice daily dosage.
USE IN SPECIFIC POPULATIONS
- Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk of fetal loss. Advise female patients to contact their healthcare provider if they become pregnant or suspect they may be pregnant during treatment with JASCAYD.
- Lactation: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JASCAYD and any potential adverse effects on the breastfed infant from JASCAYD or from the underlying maternal condition.
- Renal Impairment: Use of JASCAYD is not recommended in patients with end stage renal disease (eGFR <15 mL/minute/1.73 m2).
- Hepatic Impairment: Use of JASCAYD is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.
CL-JS-100019 4.17.2026
Click Here for Full Prescribing Information, Including Patient Information